Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors

Derek Leong; Peter E. Wu

doi:10.1503/cmaj.190107

ScienceGate Book Chapters

JOURNAL ARTICLE

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors

Derek Leong Peter E. Wu

Year: 2019 Journal: Canadian Medical Association Journal Vol: 191 (32)Pages: E894-E894 Publisher: Canadian Medical Association

DOI: 10.1503/cmaj.190107

Get Full-Text PDF Get Analytical Report

Abstract

PCSK9 is a protease that degrades hepatic LDL-C receptors. Evolocumab and alirocumab are fully human monoclonal antibodies administered as subcutaneous injections that inhibit PCSK9, preserving receptor availability to clear circulating LDL-C.[1][1],[2][2] In randomized, placebo-controlled trials

Keywords:

Kexin Proprotein convertase Subtilisin PCSK9 Medicine Computer science Bioinformatics Endocrinology LDL receptor Biology Biochemistry Cholesterol Enzyme Lipoprotein

Metrics

Cited By

0.27

FWCI (Field Weighted Citation Impact)

Refs

0.58

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Lipoproteins and Cardiovascular Health

Health Sciences → Medicine → Surgery

Computational Drug Discovery Methods

Physical Sciences → Computer Science → Computational Theory and Mathematics

Microbial Metabolism and Applications

Life Sciences → Biochemistry, Genetics and Molecular Biology → Biotechnology

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors

Abstract

Metrics

Citation History

Topics

Related Documents

Proprotein convertase subtilisin kexin type 9 (PCSK9)

Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Proprotein convertase subtilisin/kexin 9 (PCSK9)

Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?